Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;25(9):2784-2788.
doi: 10.1111/dom.15167. Epub 2023 Jun 13.

The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying

Shweta Urva  1 , Libbey O'Farrell  1 , Yu Du  1 , Mei Teng Loh  1 , Andrea Hemmingway  1 , Hongchang Qu  1 , Jorge Alsina-Fernandez  1 , Axel Haupt  1 , Zvonko Milicevic  1 , Tamer Coskun  1
Affiliations

The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying

Shweta Urva et al. Diabetes Obes Metab. 2023 Sep.
No abstract available

Keywords: GIP; GLP-1; glucagon; type 2 diabetes; weight control.

PubMed Disclaimer

References

REFERENCES

    1. Holst JJ. The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 2019;96:46-55.
    1. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab. 2021;23(S3):5-29.
    1. Murthy SN, Ganiban G. Effect of the secretin family of peptides on gastric emptying and small intestinal transit in rats. Peptides. 1988;9(3):583-588.
    1. Kreel L. Pharmaco-radiology in barium examinations with special reference to glucagon. Br J Radiol. 1975;48(573):691-703.
    1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.

LinkOut - more resources